Overview

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

Status:
Completed

Trial end date:
2003-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Quetiapine Fumarate